Following the agreement of binding terms signed in July 2024, Kedrion Biopharma Inc. and Biotest AG have now finalized the contractual terms of the long-term strategic agreement for the full commercialization and distribution of Biotest Immunoglobulin Yimmugo® in the United States.
The exclusive distribution agreement requires Biotest to supply and Kedrion to purchase minimum quantities of Yimmugo® over the initial seven-year term.
Immunoglobulin therapies, such as Yimmugo®, play a key role in managing Primary Immunodeficiencies (PID), which affect approximately 500,000 people in the US.¹
Production of the quantities needed to enter the United States began immediately after the Biologic License Application (BLA) was approved, and is ongoing. Preparations for the product’s market launch in 2025 are well underway.
“At Kedrion, we are committed to understanding the needs of patients and customers, and we are thrilled to bring Yimmugo® to the US market. In this climate of growing demand and awareness for Primary Immunodeficiencies, we see an incredible opportunity to make a meaningful impact on the lives of those who need it most“ said Bob Rossilli, Chief Commercial Officer at Kedrion.
